TD Cowen analyst Josh Jennings has maintained their neutral stance on EW stock, giving a Hold rating on February 12.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Josh Jennings has given his Hold rating due to a combination of factors including Edwards Lifesciences’s recent performance and future guidance. The company delivered strong quarterly results that surpassed market expectations, with notable revenue growth in their transcatheter aortic valve replacement (TAVR) and transcatheter mitral and tricuspid therapies (TMTT) segments. Despite these positive outcomes, the guidance for the first quarter of the upcoming year suggests sales growth will fall below the lower end of the annual range, indicating potential challenges ahead.
Additionally, while the company maintains a stable competitive position and pricing globally, and reported a satisfactory performance of new product launches in major markets, the overall growth expectations for the upcoming year remain modest. The adjusted operating margin was slightly below consensus, suggesting operational efficiencies could be improved. These mixed signals lead to a cautious approach, resulting in the Hold rating as the company navigates these uncertainties while building off its current achievements.
According to TipRanks, Jennings is a 5-star analyst with an average return of 8.3% and a 54.33% success rate. Jennings covers the Healthcare sector, focusing on stocks such as Boston Scientific, Edwards Lifesciences, and Stereotaxis.
In another report released on February 12, Morgan Stanley also maintained a Hold rating on the stock with a $75.00 price target.